TopFunds

Dexcom

NASDAQ: DXCM

Stock price

83.7 USD

(+0%) TODAY

Health Care EquipmentMedical - Devices
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
(0.2)
(0.2)
(0.1)
(0.4)
0.3
1.3
0.5
0.8
1.3
1.4
2.1
-
02Free cash flow per share
-
-
0.1
0.2
0.4
0.7
0.1
0.7
1.2
1.5
2.7
49%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
$ 402
$ 573.3
$ 718.5
$ 1,032
$ 1,476
$ 1,927
$ 2,449
$ 2,910
$ 3,622
$ 4,033
$ 4,662
27.8%
06% Change
-
42.6%
25.3%
43.6%
43.1%
30.5%
27.1%
18.8%
24.5%
11.3%
15.6%
27.8%
07Cost of revenue
(123.6)
(194.9)
(226.4)
(367.7)
(544.5)
(646.6)
(768)
(1,027)
(1,333)
(1,595)
(1,860)
31.2%
08Gross profit
278.4
378.4
492.1
663.9
931.5
1,280
1,681
1,883
2,289
2,438
2,802
26%
09% Margin
69.3%
66%
68.5%
64.4%
63.1%
66.4%
68.6%
64.7%
63.2%
60.5%
60.1%
65% A
10Operating expenses
(335.5)
(442.3)
(534.6)
(850.2)
(789.2)
(980.6)
(1,415)
(1,492)
(1,691)
(1,838)
(1,890)
18.9%
11% of Revenue
(83.5)%
(77.2)%
(74.4)%
(82.4)%
(53.5)%
(50.9)%
(57.8)%
(51.3)%
(46.7)%
(45.6)%
(40.5)%
(60.3)% A
12Operating Income
(57.1)
(63.9)
(42.5)
(186.3)
142.3
299.5
265.8
391.2
597.7
600
911.8
-
13Income tax expense
(0.1)
(0.7)
(1.6)
(0.6)
(3.1)
(268.6)
(39.9)
(49.6)
(168.9)
(132.8)
(252.1)
118.9%
14Net Income
(57.6)
(65.6)
(50.2)
(127.1)
101.1
493.6
216.9
341.2
541.5
576.2
836.3
-
15% Margin
(14.3)%
(11.4)%
(7)%
(12.3)%
6.9%
25.6%
8.9%
11.7%
15%
14.3%
17.9%
5% A
16Shares Outstanding
319,200
334,400
345,200
352,800
369,200
390,000
428,800
427,500
425,500
412,700
405,500
2.4%
17EPS Basic
(0.2)
(0.2)
(0.1)
(0.4)
0.3
1.3
0.6
0.9
1.4
1.5
2.1
-
18EPS Diluted
(0.2)
(0.2)
(0.1)
(0.4)
0.3
1.3
0.5
0.8
1.3
1.4
2.1
-
19EBITDA
(46.3)
(49.2)
(19.7)
(74.7)
213.2
376.8
377.6
565.3
916.7
945.7
1,359
-
% Margin
(11.5)%
(8.6)%
(2.7)%
(7.2)%
14.4%
19.6%
15.4%
19.4%
25.3%
23.5%
29.1%
10.6% A
20Net Interest Income (expense)
(0.4)
(0.3)
(6.1)
(20.3)
(33.9)
(68.6)
(17.1)
5.2
114.7
115.2
94.4
-
21Net Debt / EBITDA
1.8
1.8
5.4
1.6
3.3
2.7
2.9
2.7
2.2
2.1
0.3
2.4 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
86.1
94.5
441.5
1,137
446.2
817.6
1,053
642.3
566.3
606.1
917.7
26.7%
23Short-term investments
29.1
29.2
107.1
248.6
1,087
1,890
1,679
1,814
2,158
1,973
1,081
43.6%
24Accounts receivable
74.1
101.7
134.3
226.7
286.3
428.5
516.6
752.2
987.5
1,034
1,290
33.1%
25Other current assets
6.8
9.2
16.6
16.5
30
53.9
79.3
153.7
154.7
145.8
115.6
32.8%
26Inventory
35.2
45.4
45.2
70.7
119.8
234.7
357.3
306.7
559.6
542.6
629.1
33.4%
27Total Current Assets
231.3
280
744.7
1,700
1,969
3,425
3,684
3,669
4,426
4,301
4,033
33.1%
Non-Current Assets
28Net property, plant & equipment
54.7
109.4
145.6
183.1
392.8
608.6
889.9
1,136
1,185
1,403
1,637
40.5%
29Long-term investments
-
-
-
-
-
-
-
19
38.5
119.3
218
-
30Other non-current assets
6
13.4
13.8
33.4
32.8
257.1
359
568.3
615.6
661.1
451.3
54%
31Total Non-Current Assets
60.7
122.8
159.4
216.5
425.6
865.7
1,249
1,723
1,839
2,183
2,307
43.9%
Total Assets
292
402.8
904.1
1,916
2,395
4,291
4,933
5,392
6,265
6,485
6,340
36%
LIABILITIES
Current Liabilities
32Accounts payable
19
20
46.7
75.5
102.3
163.3
189.4
237.9
276.4
345.3
344.3
33.6%
33Short-term debt
2.3
-
-
-
13.6
16.5
20.5
793.1
21.1
1,227
21.6
25.1%
34Other current liabilities
45.6
82.4
92.2
146.9
244.3
434.3
510.9
808.3
1,259
1,360
1,777
44.2%
35Total Current Liabilities
66.9
102.4
138.9
222.4
360.2
614.1
720.8
1,839
1,556
2,932
2,143
41.4%
Non-Current Liabilities
36Long-term debt
-
6.7
334.3
1,018
1,147
1,823
2,137
1,352
2,573
1,361
1,368
-
37Other non-current liabilities
3.9
9.9
11.5
12.7
5.7
26.9
33
68.7
67
89.4
83.3
35.8%
38Total Non-Current Liabilities
3.9
16.6
345.8
1,030
1,152
1,850
2,170
1,421
2,640
1,450
1,451
80.8%
39Total Liabilities
70.8
119
484.7
1,253
1,512
2,464
2,891
3,260
4,196
4,382
3,594
48.1%
SHAREHOLDERS` EQUITY
40Common stock
0.1
0.1
0.1
0.1
0.1
0.1
0.4
0.4
0.4
0.4
0.4
14.9%
41Retained earnings / (deficit)
(555.4)
(621)
(671.8)
(798.9)
(695.7)
(202.1)
138.7
479.9
1,021
1,598
2,434
-
42Accumulated other comprehensive income / (loss)
(0.3)
(1)
(2.6)
1.5
2.3
3.2
0.5
(11.6)
(16.7)
(8)
115
-
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
221.2
283.8
419.4
663.3
882.6
1,827
2,042
2,132
2,069
2,103
2,746
28.6%
45Total Liabilities and shareholders' Equity
292
402.8
904.1
1,916
2,395
4,291
4,933
5,392
6,265
6,485
6,340
36%
46Total Debt
2.3
6.7
334.3
1,018
1,160
1,840
2,158
2,145
2,594
2,587
1,390
89.7%
47Net Debt
(83.8)
(87.8)
(107.2)
(119.4)
713.9
1,022
1,105
1,503
2,028
1,981
472
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
(57.6)
(65.6)
(50.2)
(127.1)
101.1
493.6
216.9
341.2
541.5
576.2
836.3
-
49Depreciation & amortization
10.8
15
16.1
29.1
48.7
67.1
102
155.9
186
217.7
251.8
37%
50Share-based compensation expense
82.7
110.8
106.2
101.9
102.7
119.4
113.4
126.5
150.8
170.4
159.6
6.8%
51Changes in working capital and other assets
13.1
(4)
19.9
119.3
62
(204.5)
10.2
45.9
(129.8)
25.2
193
30.9%
52Net cash flows from operating activities
49
56.2
92
123.2
314.5
475.6
442.5
669.5
748.5
989.5
1,441
40.2%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(33.3)
(55.7)
(66)
(67.1)
(180)
(199)
(389.2)
(364.8)
(236.6)
(358.8)
(363.5)
27%
54Purchases of investments / marketable securities
(45.2)
(39.2)
(171.8)
(453.5)
(2,032)
(3,058)
(2,473)
(2,266)
(3,200)
(2,658)
(1,266)
39.6%
55Proceeds from maturities of marketable securities
27.5
38.7
93.4
392.1
1,196
2,251
2,666
2,128
2,947
2,824
2,165
54.7%
56Other investing activities
(0.5)
0.3
-
(11.3)
-
(11.3)
(20.1)
(18.2)
(17.6)
(15.5)
0.6
-
57Net cash flows from investing activities
(51.5)
(55.9)
(144.4)
(139.8)
(1,015)
(1,018)
(216.1)
(521.5)
(507.2)
(207.5)
536
-
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
19.1
10.4
10.1
(89.2)
11.9
15.3
20.3
(535.2)
(662.1)
(721.8)
(471.9)
-
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
(2.3)
(2.3)
389
836.6
-
906.2
-
-
443.3
-
(1,208)
87.1%
61Other financing activities
-
-
-
(37)
(1.2)
(9.4)
(9.9)
(17.3)
(99.8)
(13)
(7)
-
62Net cash flows from financing activities
16.8
8.1
399.1
710.4
10.7
912.1
10.4
(552.5)
(318.6)
(734.8)
(1,686)
-
63Increase (decrease) in cash and cash equivalents
14.3
8.4
347
695.6
(690.7)
371.8
235.4
(410.3)
(75.8)
39.8
311.8
36.1%
64Cash and equivalents, ending balance
86.1
94.5
441.5
1,137
446.4
818.2
1,054
643.3
567.5
607.3
919.1
26.7%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
15.7
0.5
26
56.1
134.5
276.6
53.3
304.7
511.9
630.7
1,077
52.6%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Dexcom (DXCM) financial statements and performance

Explore Dexcom (DXCM) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.